Press Releases

July 31, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO , July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
July 29, 2020 at 12:30 AM EDT

Summary Toggle Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

SAN DIEGO , July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
July 28, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO , July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
July 23, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO , July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage

PDF Version
July 21, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Human dosing of LUNAR-COV19 expected soon Anti-Spike Glucoproteins Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration SAN

PDF Version 192.1 KB
July 1, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO , July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics

PDF Version
June 29, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics to be Added to Russell 2000® Index

SAN DIEGO , June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

PDF Version
June 11, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

SAN DIEGO , June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

PDF Version
June 5, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO , June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

PDF Version
May 21, 2020 at 8:30 AM EDT

Summary Toggle Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc.

PDF Version